• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Erectile Dysfunction - Pipeline Review, Q1 2011 - Product Image

Erectile Dysfunction - Pipeline Review, Q1 2011

  • ID: 1574076
  • February 2011
  • 65 pages
  • Global Markets Direct

Erectile Dysfunction - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Erectile Dysfunction - Pipeline Review, Q1 2011', provides an overview of the Erectile Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. 'Erectile Dysfunction - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Erectile Dysfunction.
- A review of the Erectile Dysfunction products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction Overview
Therapeutics Development
An Overview of Pipeline Products for Erectile Dysfunction
Erectile Dysfunction Therapeutics under Development by Companies
Erectile Dysfunction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Erectile Dysfunction Therapeutics Development
Johnson & Johnson
Eli Lilly and Company
Vectura Group plc
Chong Kun Dang Pharmaceutical
Dong-A Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
VIVUS, Inc.
Warner Chilcott Limited
Bayer AG
NovaDel Pharma, Inc.
Palatin Technologies, Inc.
Plethora Solutions Holdings plc
Rexahn Pharmaceuticals, Inc.
Baylor College of Medicine
Global Health Ventures Inc.
Fabre-Kramer Pharmaceuticals, Inc.
Quatrx Pharmaceutical Company
Ion Channel Innovations, LLC
Universities/Institutes Involved in Erectile Dysfunction Therapeutics Development
Erectile Dysfunction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Androgel + Tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avanafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Invicorp - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Priligy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SK3530 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitaros - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WC3036 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WC3043 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zydena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Alfuzosin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluvastatin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Folic Acid + Tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viagra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zydena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Erectile Dysfunction - Featured News
1. Dec 06, 2010: VIVUS Announces Positive Results From Long-Term Phase III Study Of Avanafil In Erectile Dysfunction
2. Nov 15, 2010: Apricus Biosciences Receives Canadian Approval For Vitaros As First Line Therapy For Erectile Dysfunction
3. Oct 15, 2010: NovaDel Reports Positive Data From Pilot Pharmacokinetic Study Comparing Duromist To Viagra Tablet
4. Oct 12, 2010: Dong-A Launches Zydena For Daily Treatment Of Erectile Dysfunction In Korea
5. Sep 02, 2010: Palatin Technologies Completes First Cohort Dosing Study Of Bremelanotide For The Treatment Of Sexual Dysfunction
6. Aug 17, 2010: Palatin Announces Positive Safety Results From Phase I Subcutaneous Bremelanotide Trial In Men
7. Jun 24, 2010: Nexmed Receives First Patent For Vitaros In Japan
8. Jun 23, 2010: NexMed Receives Screening Acceptance Letter From Health Canada For Vitaros
9. Jun 10, 2010: Nexmed Provides Update On Canadian Filing For Vitaros
10. Jun 07, 2010: VIVUS Announces Positive Results From Phase III Study Of Avanafil In Diabetics With Erectile Dysfunction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Erectile Dysfunction, 2011
Products under Development for Erectile Dysfunction – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Johnson & Johnson, 2011
Eli Lilly and Company, 2011
Vectura Group plc, 2011
Chong Kun Dang Pharmaceutical, 2011
Dong-A Pharmaceutical Co., Ltd., 2011
Mitsubishi Tanabe Pharma Corporation, 2011
Pfizer Inc., 2011
VIVUS, Inc., 2011
Warner Chilcott Limited, 2011
Bayer AG, 2011
NovaDel Pharma, Inc., 2011
Palatin Technologies, Inc., 2011
Plethora Solutions Holdings plc, 2011
Rexahn Pharmaceuticals, Inc., 2011
Baylor College of Medicine, 2011
Global Health Ventures Inc., 2011
Fabre-Kramer Pharmaceuticals, Inc., 2011
Quatrx Pharmaceutical Company, 2011
Ion Channel Innovations, LLC, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Erectile Dysfunction, 2011
Products under Development for Erectile Dysfunction – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos